JP2005523335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523335A5 JP2005523335A5 JP2003587405A JP2003587405A JP2005523335A5 JP 2005523335 A5 JP2005523335 A5 JP 2005523335A5 JP 2003587405 A JP2003587405 A JP 2003587405A JP 2003587405 A JP2003587405 A JP 2003587405A JP 2005523335 A5 JP2005523335 A5 JP 2005523335A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- antibody consisting
- antibody
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37546202P | 2002-04-25 | 2002-04-25 | |
| PCT/US2003/010473 WO2003090772A1 (en) | 2002-04-25 | 2003-04-17 | Method for treating anxiety and mood disorders in older subjects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523335A JP2005523335A (ja) | 2005-08-04 |
| JP2005523335A5 true JP2005523335A5 (enExample) | 2006-06-01 |
Family
ID=29270644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003587405A Ceased JP2005523335A (ja) | 2002-04-25 | 2003-04-17 | 高齢被検体の不安障害および気分障害の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050129691A1 (enExample) |
| EP (1) | EP1501531B1 (enExample) |
| JP (1) | JP2005523335A (enExample) |
| AT (1) | ATE419871T1 (enExample) |
| AU (1) | AU2003223474B2 (enExample) |
| CA (1) | CA2483729A1 (enExample) |
| DE (1) | DE60325717D1 (enExample) |
| ES (1) | ES2318123T3 (enExample) |
| WO (1) | WO2003090772A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05003621A (es) * | 2002-10-09 | 2005-10-19 | Rinat Neuroscience Corp | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| DE602004027348D1 (de) | 2003-02-10 | 2010-07-08 | Applied Molecular Evolution | Abeta-bindende moleküle |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| US20060153772A1 (en) * | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
| UY29504A1 (es) * | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| SG10201706600VA (en) | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| JP5419131B2 (ja) * | 2005-12-12 | 2014-02-19 | エーシー イミューン ソシエテ アノニム | 治療的特性を有するβ１〜４２特異的モノクローナル抗体 |
| TWI551607B (zh) * | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| ES2535641T3 (es) | 2007-01-18 | 2015-05-13 | Eli Lilly & Company | Amiloide beta Fab pegilado |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| SG182192A1 (en) * | 2007-06-12 | 2012-07-30 | Ac Immune Sa | Humanized antibodies to amyloid beta |
| US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| RU2542967C2 (ru) * | 2007-10-05 | 2015-02-27 | Дженентек, Инк. | Применение антитела против амилоида бета при глазных заболеваниях |
| CA2701793C (en) | 2007-10-05 | 2017-04-25 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US5837672A (en) * | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| DK1409654T3 (da) * | 1999-06-16 | 2008-12-08 | Boston Biomedical Res Inst | Immunologisk styring af beta-amyloid-niveauer in vivo |
| KR100767146B1 (ko) * | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
| US7166478B2 (en) * | 2002-03-12 | 2007-01-23 | Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. | Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses |
-
2003
- 2003-04-17 JP JP2003587405A patent/JP2005523335A/ja not_active Ceased
- 2003-04-17 AT AT03719604T patent/ATE419871T1/de not_active IP Right Cessation
- 2003-04-17 DE DE60325717T patent/DE60325717D1/de not_active Revoked
- 2003-04-17 EP EP03719604A patent/EP1501531B1/en not_active Revoked
- 2003-04-17 AU AU2003223474A patent/AU2003223474B2/en not_active Ceased
- 2003-04-17 US US10/512,527 patent/US20050129691A1/en not_active Abandoned
- 2003-04-17 WO PCT/US2003/010473 patent/WO2003090772A1/en not_active Ceased
- 2003-04-17 ES ES03719604T patent/ES2318123T3/es not_active Expired - Lifetime
- 2003-04-17 CA CA002483729A patent/CA2483729A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523335A5 (enExample) | ||
| Kastanenka et al. | Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice | |
| Díaz-Moreno et al. | Noggin rescues age-related stem cell loss in the brain of senescent mice with neurodegenerative pathology | |
| Angelucci et al. | Investigating the neurobiology of music: brain-derived neurotrophic factor modulation in the hippocampus of young adult mice | |
| Wu et al. | LINGO‐1 antibody ameliorates myelin impairment and spatial memory deficits in the early stage of 5 XFAD mice | |
| Kumru et al. | Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations | |
| Vickers | A vaccine against Alzheimer’s disease: Developments to date | |
| JP2005500389A5 (enExample) | ||
| WO2004091510A3 (en) | Recombinant il-9 antibodies and uses thereof | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| WO2008067464A3 (en) | NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES | |
| EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
| DE60229051D1 (de) | Humanisierte antikörper | |
| JP2008501758A5 (enExample) | ||
| Hosseinzadeh et al. | Evaluation of Helicobacter pylori infection in patients with common migraine headache | |
| Zhang et al. | Triggering receptor expressed on myeloid cells 2 overexpression inhibits proinflammatory cytokines in lipopolysaccharide‐stimulated microglia | |
| Zong et al. | Molecular mechanisms of exercise intervention in alleviating the symptoms of autism spectrum disorder: Targeting the structural alterations of synapse | |
| NO20060901L (no) | Ny anvendelse av antisekretorisk faktor | |
| Aït-Khaled et al. | Management of asthma: the essentials of good clinical practice [Educational Series: Asthma. Serialised guide. Management of asthma: the essentials of good clinical practice. Number 1 in the series] | |
| Romano et al. | Genotype–phenotype spectrum and correlations in Xia‐Gibbs syndrome: Report of five novel cases and literature review | |
| Bin et al. | Neuroprotective effect of AG490 in experimental traumatic brain injury of rats | |
| EP2216043A4 (en) | USE OF GSE24.2 INDUCTOR AGENTS FOR DEVELOPING PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH CELL SENESCENCE | |
| CA2505506A1 (en) | Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils | |
| ATE449769T1 (de) | 3-(4-ää4-(4ää3-(3,3-dimethyl-1- piperidinyl)propyläoxyüphinylü-1- piperidinylcarbonylü-1-naphthalinyl)propan- oder propensäure als h1- und h3-rezeptor-antagonisten zur behandlung entzündlicher und/oder allergischer erkrankungen | |
| McKeith | Dementia in Parkinson's disease: common and treatable |